We sought to determine whether a multidisciplinary team (MDT) approach to lung cancer care yields superior outcomes to a traditional care model. The present investigation included > 4000 patients and compared the survival outcomes between lung cancer patients participating in an MDT program and those receiving traditional care. The results suggest a significant survival benefit with the MDT approach for the diagnosis and treatment of lung cancer. Background: Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. Patients and Methods: The Stony Brook Cancer Center Registry was used to identify all lung cancer cases diagnosed between 2002 and 2016. We compared survival outcomes among 1956 lung cancer patients participating in our institution's Lung Cancer Evaluation Center's (LCEC) MDT program and 2315 lung cancer patients receiving traditional care. Log-ranks tests were used to evaluate differences in the 1-, 3-, 5-, and 10-year survival outcomes between the 2 groups. To address inherent biases, Cox proportional hazard models were used to estimate the effects on survival outcomes and adjust for possible confounders. Propensity matching was also performed to account for the effects of selection bias. Results: The 5-year survival rates in the propensity-matched sample were one third greater among LCEC patients compared with those receiving a traditional care approach (33.6% vs. 23.0%; P < .001). After adjusting for potential confounders in the multivariable propensity-matched analyses, the LCEC model demonstrated a significant beneficial effect on 5-year survival outcomes compared with the standard treatment model (hazard ratio, 0.65; 95% confidence interval, 0.54-0.77). Conclusion: The results of the present investigation suggest an improved survival benefit from usage of an MDT model versus a traditional care model in the treatment of lung cancer. Despite the use of sophisticated statistical methods to mitigate bias in a nonrandomized study, additional research is needed to determine the extent to which an MDT approach for lung cancer influences patient outcomes.
Introduction
Lung cancer remains the leading cause of cancer death worldwide with a 5-year survival rate of 17%. 1 Most cases of lung cancer are detected by imaging modalities and are typically first reported to an internist or primary care physician, followed by referral to a pulmonologist and subsequent referrals to an oncologist, a thoracic surgeon, and/or a radiation oncologist. At each of these steps, the patient and responsibility of care is handed over to the next physician. This serial treatment care model has been accentuated in recent years by the ultra-specialization of physicians and is often perceived as slow, fragmented, and poorly coordinated. 2 Multidisciplinary teams (MDTs) of specialized health care professionals have been shown to improve the outcomes of patients with various cancer types 3 ; however, the evidence for lung cancer in this regard, especially in the United States, has been scarce. [4] [5] [6] To date, questions regarding whether MDTs contribute this model of care simply escalates expenses without cost efficiency and effectiveness remain. In 2000, a multidisciplinary program, the Lung Cancer Evaluation Center (LCEC), was established at Stony Brook University Hospital (SBUH) with the intent of implementing an MDT model of care to evaluate, treat, and monitor patients with lung cancer. SBUH also maintains a cancer registry, which captures all patients with a diagnosis of any cancer at SBUH. This repository is tasked with recording the demographic data, medical history, cancer treatment, and outcomes data for all cancer patients, including survival status and death certification, on an annual basis. The purpose of the present investigation was to use the cancer registry to compare the short-term and long-term survival outcomes of lung cancer patients treated within the LCEC's well-defined MDT program with those of patients who had received a traditional model of cancer care at SBUH.
Patients and Methods

Patient Population
The present retrospective investigation included all lung cancer cases diagnosed between 2002 and 2016 entered into the SBUH cancer registry. Cases reported during the 15-year period were divided into 2 groups: LCEC and non-LCEC. Crossing the registry data with the clinical LCEC database yielded a study sample of 1956 lung cancer patients in the LCEC group and 2315 patients in the non-LCEC group. The LCEC patients were defined as those who had, at a minimum, one clinical encounter with the MDT physicians and case presentation at the tumor board. Data abstracted from the registry included age at diagnosis, date of diagnosis (defined as the date the cancer diagnosis was clinically documented at SBUH), gender, race, smoking and alcohol history, marital status, diabetes, hypertension, family history of cancer, cancer histologic type when diagnosed at SBUH, tumor stage, treatment modalities, and survival status and duration. The registry does not capture performance status, preceding treatment, or the date of first detection.
Setting
SBUH is a public suburban university hospital in the Northeast serving the County of Suffolk, which includes w 1.5 million people. Hospital personnel include full-time faculty and staff, as well as community physicians. As in many such settings, care is not institutionally dictated, and the principle of "choice" by patient and physician is upheld, making it possible for an LCEC physician to treat a non-LCEC patient. This was especially true for patients receiving radiation therapy.
LCEC Multidisciplinary Care and Surveillance Model
The LCEC program includes thoracic surgery, interventional pulmonology, medical oncology, radiation oncology, and 2 dedicated nurse practitioners as the core group. Interventional radiology, radiation therapy, chest radiology, and social and nutritional support are also on site. Referrals to LCEC, from within and external to SBUH, are provided at the discretion of the referring physician. Physicians who opt to treat their patients outside the program do so without institutional pressure.
LCEC patients are seen in 1 location, with most initially evaluated in an outpatient setting. Ancillary help is available to facilitate referrals, authorizations, and appointments which shift the burden for these from the patient to the clinic. Patients with concerning findings are further discussed at an MDT tumor board conference. All LCEC patients and those under surveillance for the development of lung cancer are followed using the National Comprehensive Cancer Network and Fleischner Society guidelines as the standards of care.
Statistical Analysis
Descriptive statistics are presented separately for LCEC and non-LCEC cases. Differences between the 2 groups were determined using c 2 tests for categorical data and t tests for continuous data. Logrank tests were used to evaluate differences in the 1-, 3-, 5-, and 10-year survival outcomes between LCEC and non-LCEC patients, stratified by tumor stage. Cox proportional hazard (CPH) models were used to provide estimates of factor effects on survival, with adjustment for possible confounders, including LCEC status, age at diagnosis, gender, race, marital status, smoking status, alcohol consumption, history of diabetes, history of hypertension, family history of cancer, tumor stage, and histologic type. Additionally, the date of entry into the registry was included in the model to adjust for the possible influence of temporal confounding related to improvement in survival outcomes over time. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented. To address the differences between groups resulting from selection, referral, or other biases, propensity-matched analyses were also conducted. The LCEC and non-LCEC patients were matched on age, gender, race, cancer type, stage, and treatment (surgery vs. no surgery). Any crossover patient entering or exiting LCEC was defined as an LCEC patient. To address the possible effect of crossover for those exiting LCEC care prematurely, a subgroup analysis of patients who were actively treated or who had died under the care of the LCEC was performed.
SPSS, version 21, was used to conduct these analyses. The SBUH's committee on research involving human subjects approved this study (approval no., 1007483-1).
Results
The present investigation included 4271 patients with a diagnosis of lung cancer at SBUH between 2002 and 2016. The demographic and other characteristics of all lung cancer cases, stratified by LCEC status, are presented in Table 1 . The average age at diagnosis among LCEC and non-LCEC patients was 67 years, and the racial composition for both groups was predominantly white (93%-94%). The groups were also similar in gender distribution, smoking history, and marital status. Significant differences were noted between the 2 groups with respect to a history of alcohol consumption, diabetes, hypertension, a family history of cancer, and tumor histologic type. Only 18.7% of LCEC patients had histologic information that had not been certified by the SBUH pathology department or was otherwise unknown compared with 34.8% of non-LCEC patients (P < .001; Table 1 ). Since cancer care occurs predominantly in the outpatient setting, the noted asymmetry likely resulted from the predominant number of non-LCEC patients having their tissue confirmation performed external to SBUH.
The LCEC patients were registered at a significantly earlier stage than were the non-LCEC patients, with lung cancer diagnosed in approximately one half of LCEC patients at stage I/II compared with 20% of non-LCEC cases. Additionally, the percentage of patients undergoing surgery was significantly greater among LCEC than among non-LCEC patients (39.8% vs. 15.8%; P < .001), likely due to the earlier stage at encounter in the former group and low resectability of the latter. The results for radiation and chemotherapy reflected the use of either of these modalities for any cause during the observation period.
The 1-, 3-, 5-, and 10-year survival rates for patients with a diagnosis of lung cancer at SBUH during the 15-year period, stratified by LCEC status and stage, are listed in Table 2 . Shortterm and long-term survival rates were both significantly greater among LCEC patients compared with non-LCEC patients at all stages. As expected, survival rates decreased with higher stage and increased time since the diagnosis. At 5 years, LCEC patients with stage II or more advanced lung cancer had survival outcomes that were twice as great as those of comparable non-LCEC patients.
To address selection, reporting, or other biases, propensitymatched analyses were performed to balance LCEC and non-LCEC patients for potentially related covariates. The 1-, 3-, 5-, and 10-year overall survival outcomes for all patients and for the subgroup of propensity-matched cases are listed in Table 3 . At 1-year from the date of diagnosis, the overall survival rates for all patients were 72.6% and 44.8% for LCEC and non-LCEC patients, respectively (P < .001). At 5-years, survival rates were 3.5 times greater (31.7% vs. 9.1%, respectively; P < .001) and 10-year survival rates were 14.5% and 4.4% for LCEC and non-LCEC patients, respectively (P < .001).
The propensity-matched sample for year 1 included 1892 of the 4271 total cases. Despite this significantly reduced sample size, the matched analyses yielded findings consistent with those obtained by including all patients. Survival rates at 1-year for the propensitymatched cases were 76.5% and 69.9% (P ¼ .003) for LCEC and non-LCEC groups, respectively. Significant survival differences between groups were also observed at 3-and 5-years. The survival advantage for LCEC was no longer detectable at 10-years after first examination at SBUH, although the sample size at that point was limited.
We further evaluated survival outcomes using Cox PHMs to adjust for possible confounders. The findings indicated that LCEC patients had a significantly improved 5-year survival benefit compared with non-LCEC patients (HR, 0.64; 95% CI, 0.57-0.73; Table 4 ). Male gender contributed to decreased survival (HR, 1.32; 95% CI, 1.18-1.47) and being married seemed to have a protective effect (HR, 0.83; 95% CI, 0.74-0.92). Ever smokers (HR, 1.29; 95% CI, 1.03-1.60) and those with a history of diabetes (HR, 1.20; 95% CI, 1.02-1.42) were also less likely to survive for 5 years after the diagnosis of lung cancer. In addition, advanced stage (HR, 1.66; 95% CI, 1.58-1.76) negatively affected 5-year survival. The propensity-matched models yielded similar results, indicating significantly better survival at 5-years for LCEC patients compared with non-LCEC patients (HR, 0.65; 95% CI, 0.54-0.77).
To address the influence of crossover in our investigation, overall and stage-stratified survival analyses were subsequently conducted for the subgroup of patients who had actively remained under the care of the MDT. Among the full cohort of 1956 LCEC patients, 414 cases became inactive at some point after entry into the program. The reasons for inactivity included moving away, selecting another care provider, and other (mainly unspecified) explanations. After excluding those cases who had become inactive, the results for the remaining 1542 patients were highly consistent with the main study findings, yielding significantly improved overall 1-, 3-, 5-, and 10-year survival rates (P < .001 for all periods) for LCEC compared with non-LCEC patients. Likewise, stage-stratified survival rates among LCEC patients (noninclusive of crossover cases) similarly outperformed those achieved by the non-LCEC group. 
Effect of an MDT Approach on Lung Cancer Survival Outcomes
Discussion
It has been difficult to show an advantage of an MDT model compared with the traditional standard of care approach for lung cancer as currently practiced in the United States. The methodologic challenges are numerous, as randomized trials in which care decisions are removed from both the patient and the physician are inherently challenging to design and not altogether feasible. The present study interrogated an institutional tumor registry to assess the outcomes of patients with a diagnosis of lung cancer. To the best of our knowledge, the present study is the first in the United States to evaluate "real world" survival outcomes among a large number of lung cancer patients receiving MDT care compared with a standard model of care. Short-term and long-term survival rates were significantly greater among LCEC compared to non-LCEC patients with a lung cancer diagnosis during the past 15 years at SBUH. Our results highlight the potential benefit of a multidisciplinary care model for the evaluation, diagnosis, treatment, and monitoring of patients with concerning pulmonary findings.
A Multidisciplinary Care Model for Cancer
Although a systematic review of the reported data, including 51 peer-reviewed reports found that MDTs yielded better clinical outcomes and improved survival for colorectal cancer, 7-10 head and neck cancer, 11,12 breast cancer, 13,14 esophageal cancer, 15 and lung cancer, 3, 16 widespread adoption of such clinic models has met with challenges. This is likely due to the limited evidence base to date documenting a true survival benefit. The sparse evidence supporting usefulness of MDTs in lung cancer has primarily originated from studies in the United Kingdom and Australia. In one arly investigation in Glasgow including 323 patients with inoperable nonesmall cell lung cancer (NSCLC), 117 patients were treated in a newly implemented MDT approach in 
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2001 and 126 had received a traditional model of care in 1997. 17 The study found improved survival outcomes in the former group, with median survival times of 6.6 months and 3.2 months (P < .001) in the MDT and traditional care groups, respectively. In another study, from Australia, improved survival was reported as a result of the implementation of MDT meetings for patients with inoperable NSCLC. 16 During a 1-year period, patients whose cases had been discussed at a multidisciplinary team meeting had a mean survival duration of 280 days compared with 205 days for those whose cases were not discussed (P ¼ .048). However, a second study in Australia of 988 lung cancer patients identified from a Clinical Cancer Registry in Sydney compared the patterns of care among 504 lung cancer patients whose cases were presented at MDT meetings against the patterns of care for 484 patients whose cases were not discussed by an MDT team. The investigation found that MDT discussion was associated with better receipt of certain treatment modalities (ie, chemotherapy and radiation therapy) but did not, however, improve survival.
18
A study by Freeman et al 5 of > 1200 NSCLC patients was one of the first in the United States to report a benefit from the implementation of a multidisciplinary conference for the treatment of lung cancer. However, that investigation did not evaluate survival outcomes. 5 Although the findings from the present study support a benefit of such multidisciplinary discussions on survival, the definition used to classify LCEC patients did not consider the effect of patient crossover after the initial consultation. Thus, subsequent overall and stage-stratified subgroup survival analyses were conducted among patients remaining in the program, and the results were consistent with those from the full cohort. These findings support a survival benefit from participation in the MDT program.
Survival Outcomes
Lung cancer has the highest mortality rate of all cancer types.
1
Although some minimal improvements have occurred during the past decade, the 1-and 5-year survival rates are still < 50% and < 20%, respectively, in the United States. 19 Although survival rates among non-LCEC lung cancer patients were consistent with national estimates, LCEC patients had significantly improved outcomes, suggesting a potential survival benefit of an MDT approach to lung cancer care. It has been well-established that improved survival is highly related to early disease detection. In the present investigation, statistically significant differences in the staging distribution of lung cancer between LCEC and non-LCEC cases were observed. Approximately 50% of LCEC cases were recorded at stage I/II compared with 20% of non-LCEC cases. A number of explanations are possible. First, this finding could likely be a reflection of selection bias. Second, cancer care in the United States is overwhelmingly an outpatient endeavor. A tumor registry requires usage of some hospital-based services, in particular, pathology, and is almost always linked to a hospital admission. As such, non-LCEC patients had to be admitted to be captured in the registry, thereby explaining the preponderance for later stage cancer in the non-LCEC group. Third, an additional analysis indicated that 30% of LCEC cancer cases were first discovered during surveillance, suggesting an earlier stage at detection.
Study Limitations
Although the present investigation was strengthened by the large cohort and a 15-year longitudinal study period, it had notable limitations. First, the retrospective study design is prone to uncontrolled selection, referral, and treatment biases, which can include differences in patient access to provider practices. Noted imbalances in stage distribution, histologic features, treatment, and other variables could be indicative of such biases and might thereby have affected the differences in survival outcomes. To address such biases, we conducted propensitymatched analyses, which, although somewhat attenuated, supported the survival benefit of an MDT model 5 years. However, the applied propensity matching was not likely to fully abate all potential biases, as the analyses were limited to matching of only known factors.
Second, the registry data used in the present investigation had some inherent disadvantages. One concern is that using date of entry into a tumor registry as time zero will not necessarily equate to the date of diagnosis, as patients might have had cancer for a significant duration before presentation. In addition, reporting differences could have been encountered in our study. Significant asymmetries were found between the LCEC and non-LCEC cases with respect to histologic type and stage distribution. The former likely resulted from performance of the pathologic assessment at SBUH for LCEC cases (which further facilitated entry of the diagnosis into the system) but non-LCEC cases could have had their tissue confirmation performed elsewhere and thereby were not captured in the registry. To address the potential biases related to differences in disease severity between the 2 groups, we performed stage-stratified and propensity-matched evaluations. The findings favored the MDT model, regardless of stage, in both sets of analyses. In addition, the cancer registry did not capture performance status or other potentially confounding variables that might have affected the study findings. It is unclear, however, to what extent, and in which direction, such factors would influence the outcomes.
A further limitation of our investigation was that it did not enable quantification of the effect of each of the program's independent features. Thus, we were unable to assess to what degree the multidisciplinary clinic, tumor board discussions, shared decision treatment plans, surveillance and monitoring protocols, and other components of the LCEC program contributed (individually and cumulatively) to the observed improvements in survival. These challenges highlight the need for well-designed prospective studies to address the issues of missing data and biases inherent to retrospective study designs. We acknowledge, however, that such a study would be difficult to implement and execute in a public hospital setting because of the prevailing health care system infrastructure in the United States by which patient and physician "choice" guide clinical practice.
Finally, the study findings were based on data from the cancer registry of a single institution in the Northeast; thus, the generalizability of the results may be limited. Despite these limitations, however, our data suggest a benefit of an MDT care model for lung cancer.
Conclusion
The findings from the present investigation add to a limited but increasing evidence base supporting the use of MDTs in cancer Effect of an MDT Approach on Lung Cancer Survival Outcomes care. The short-and long-term survival rates among patients with lung cancer participating in the SBUH LCEC's MDT program were significantly greater than those achieved by the local standard model of care. Additional research is warranted to evaluate the magnitude and true effect of MDTs on lung cancer treatment outcomes.
Clinical Practice Points
Although it is generally believed that MDT models of cancer care improve patient outcomes compared with the traditional serial care approach, data are sparse, especially for lung cancer. To the best of our knowledge, ours is the first large-scale report in the United States comparing survival outcomes among lung cancer patients treated by an MDT versus traditional cancer care model. The present investigation included > 4000 patients with lung cancer identified by an institutional cancer registry spanning a 15-year observation period from 2002 to 2016. The present study provides "real world" data supporting a survival benefit for patients receiving a multidisciplinary treatment approach to their lung cancer care.
